Vector, Russia’s state virology and biotechnology research center, developed a vaccine against Covid-19 that can be administered by the nasal route.
Vaccines differ not only from their functional origin, but also from the method in which they are administered, which is why one of our solutions seeks to avoid intramuscular immunization and opt for intranasal immunization, said Rinat Maksiútov, director of that center.
Speaking on Saturday to the Rossiya 1 channel, Maksiútov explains that a large-scale preclinical study of these drugs has already been launched, both in terms of efficiency and safety.
The center plans to begin clinical trials of its coronavirus vaccine, which causes COVID-19, in late June or early July, to complete in mid-September, Maksiútov estimates.
The director of Vector also points out that the animals in which the new vaccine has been tested tolerated it well, without presenting adverse reactions.
“When the vaccine was introduced, there were no increases in temperature and we also did not see any undesirable reactions,” he adds.
